Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial

Abstract

BackgroundHigh oxidative stress and chronic inflammation can contribute to the pathogenesis of coronary artery disease (CAD). Coenzyme Q10 is an endogenous lipid-soluble antioxidant. Statins therapy can reduce the biosynthesis of coenzyme Q10. The purpose of this study was to investigate the effects of a coenzyme Q10 supplement (300 mg/d; 150 mg/b.i.d) on antioxidation and anti-inflammation in patients who have CAD during statins therapy.MethodsPatients who were identified by cardiac catheterization as having at least 50% stenosis of one major coronary artery and who were treated with statins for at least one month were enrolled in this study. The subjects (n = 51) were randomly assigned to the placebo (n = 24) and coenzyme Q10 groups (Q10-300 group, n = 27). The intervention was administered for 12 weeks. The concentrations of coenzyme Q10, vitamin E, antioxidant enzymes activities (superoxide dismutase, catalase, and glutathione peroxidase), and inflammatory markers [C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6)] were measured in the 42 subjects (placebo, n = 19; Q10-300, n = 23) who completed the study.ResultsThe levels of the plasma coenzyme Q10 (P < 0.001) and antioxidant enzymes activities (P < 0.05) were significantly higher after coenzyme Q10 supplementation. The levels of inflammatory markers (TNF-α, P = 0.039) were significantly lower after coenzyme Q10 supplementation. The subjects in the Q10-300 group had significantly higher vitamin E (P = 0.043) and the antioxidant enzymes activities (P < 0.05) than the placebo group at week 12. The level of plasma coenzyme Q10 was significantly positively correlated with vitamin E (P = 0.008) and antioxidant enzymes activities (P < 0.05) and was negatively correlated with TNF-α (P = 0.034) and IL-6 (P = 0.027) after coenzyme Q10 supplementation.ConclusionCoenzyme Q10 supplementation at 300 mg/d significantly enhances antioxidant enzymes activities and lowers inflammation in patients who have CAD during statins therapy.Trial registrationClinical Trials.gov Identifier: NCT01424761.

RETRACTED ARTICLE: The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome

“…In another study, CoQ10 supplementation significantly reduced the IL-6 protein and TGF-b1 and Lep mRNA levels [6]. In addition, our study was in agreement with findings in cardiac tissue [23], and CoQ10 is known to have anti-inflammatory properties in mouse liver [24] and human plasma [25]. Also, gene expression of TNF-a were significantly decreased following CoQ10 intake in an experimental model of multiple sclerosis for three weeks [26].…”

Coenzyme Q10 supplementation for diabetes and its complications: an overview

“…31,32 Thus, as well as reducing the risk of cardiovascular problems in patients with liver disease, CoQ10 supplementation may also benefit the disease process within the liver by reducing inflammation and oxidative stress, key factors in the pathogenesis of NAFLD. 33 Yesilova et al 34 found that blood CoQ10 levels were depleted in NAFLD patients, with the decrease in CoQ10 correlating with increased liver inflammation and cirrhosis.…”

Hepatoprotective effect of taurine and coenzyme Q10 and their combination against acrylamide-induced oxidative stress in rats

“…It is unique among naturally occurring and it is synthesized de novo in animals [7]. Studies have shown that the CoQ10 has free radical-scavenging activities, liver injuryreducing properties and endothelial dysfunction improving [8].…”